One headline takeaway from every specialty. Start with what matters to you.
One collection. 40 ways into the research.
Compared with no or short-duration symptoms, unresolved Long COVID was associated with 38% lower relative odds of paid work and higher odds of changing working hours.
Adults in an English population-based cohort were followed for a median of 23 months; approximately 4% had unresolved Long COVID. These adjusted associations do not establish that Long COVID caused the employment changes.In a comparison with VA controls, COVID-19 survivors had a 63% higher hazard of any cardiovascular outcome through 12 months. Hazards were also higher for heart failure, atrial fibrillation, heart attack and stroke.
Absolute event rates for this comparison are not available in this summary, and the study design is not recorded. The comparison with VA controls shows associations, not proof that infection caused each outcome.A systematic review estimated brain fog prevalence at 30% and cognitive impairment prevalence at 25% in Long COVID populations.
Both pooled prevalence estimates come from one systematic review of Long COVID populations. Definitions and contributing populations are not detailed in this summary.With breathless Long COVID, >90% of measured lung-function values were normal despite lower scores than controls. In a never-hospitalized subgroup, 14/109 (~13%) had a low lung gas-transfer measure (TLCO) and reduced xenon-MRI gas-exchange metrics.
The >90% describes measured values, not people; details of the controls are not available in this summary. The subgroup had otherwise unexplained breathlessness, and a pulmonary contribution was described as only potential.In the study, persistent immune dysfunction was detected in 60% of Long COVID patients.
The finding was detectable at 6-12 months post-infection in the study's Long COVID patients. The sample and definition of immune dysfunction are not available, so broader applicability cannot be assessed.Versus no Omicron-adapted vaccination, reported effectiveness ranged 16.6% to 67.8% for COVID-19 hospitalization and 26.6% to 75.2% for all-cause mortality. A myocarditis incidence signal was also reported.
Rapid review of adults who were neither pregnant nor immunocompromised. The myocarditis signal involved adults aged 50 years or older. Its uncertainty range was wide and included no increase; its reference group and absolute rate are unavailable here.A systematic review and meta-analysis of 52 cohort studies estimated pooled pediatric Long COVID prevalence at 18.1%. Estimates changed with the definition used.
The pooled estimate came from pediatric cohorts; definition-specific estimates ranged from 16.2% to 21.6%, showing how the chosen definition affected the result.An interim test-negative study in adults reported effectiveness of 2025-2026 COVID-19 Vaccines against COVID-19-associated hospitalization, including among adults aged 65+.
Neither the comparator for recipients of 2025-2026 COVID-19 Vaccines nor the follow-up period is available in this summary, so the effectiveness percentages are not featured.A prevalence of 20-40% was reported for histamine intolerance among Long COVID patients.
The study design and timeframe are not recorded. The diagnostic definition and sampling method are not available in this summary.Explore the specialty evidence
A systematic review and meta-analysis of COVID-19 hospitalisations reported an association between elevated C-reactive protein and severe COVID-19.
The cutoff defining elevated C-reactive protein, measurement timeframe and named reference group are not available in this summary, so the reported magnitude is not displayed.Explore the specialty evidence
Mean annual total healthcare costs for adults with Long COVID versus contemporary controls were £6681.6 vs £2039.9 in Wales and £3378.3 vs £1355.8 in England.
This England-and-Wales analysis used contemporary controls. Design and adjustment details are not available in this summary.In a systematic review and meta-analysis, COVID-19 survivors had a 41% higher relative risk of new-onset diabetes than non-infected individuals.
This pooled post-acute result is relative, not absolute. Follow-up, population details, and underlying study designs are not available in this summary, so it should not be read as causal.Globally, an estimated 6.2% of symptomatic individuals developed the studied Long COVID symptom clusters.
This estimate applies to the studied persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021; the 95% uncertainty interval was 2.4-13.3%.After 4 weeks, 68% receiving VSL#3® were fatigue responders versus 35.7% receiving placebo; Chalder Fatigue Scale scores also fell more with VSL#3® than placebo.
This randomized placebo-controlled trial involved patients with long COVID and clinically relevant fatigue. The responder definition and safety findings are not available here; the reported outcomes cover 4 weeks.The reported proportion of patients with life-threatening COVID-19 who had inborn errors of type I interferon immunity was 3.5%.
The source concerns patients with life-threatening COVID-19. Study design and sampling details are not recorded in this summary, limiting how broadly the proportion can be generalized.In reviewed U.S. evidence, COVID-19 mortality among long-term care facility residents was 4.6-fold higher than among community-dwelling individuals; residents accounted for approximately 1 in 6 COVID-19 hospitalizations.
Systematic review of U.S. evidence. All included studies covered Omicron-period data, while most also included earlier variants.Across randomized trials of adults with acute respiratory failure, nebulized heparin had a 21% lower relative risk of death from any cause than standard care or placebo.
Mortality was 17.1% with nebulized heparin and 22.1% with standard care or placebo. The major-bleeding analysis found no clear difference versus control; the supplied evidence does not specify the control regimen, and the estimate was imprecise.The estimate was 25-30% among hospitalized COVID-19 patients, rising to 45-52% in severe cases.
This came from a systematic review with meta-analysis of liver manifestations in COVID-19; definitions and the observation timeframe are not available in this summary.Among people infected with SARS-CoV-2 in southeastern Brazil, two booster doses were associated with 82% lower relative odds of Long COVID compared with a primary vaccine series.
During the Omicron period, only the second booster was associated with lower odds versus the primary series. The study design is not available in this summary, so causation cannot be established here.The cited meta-analysis reported that 50% of Long COVID patients met ME/CFS diagnostic criteria.
The diagnostic criteria and assessment timing are unavailable in this summary. The accompanying ME/CFS incidence increase has no named reference group here, so its magnitude is not interpreted.A meta-analysis reported acute kidney injury incidence of 17-28% among hospitalized patients with COVID-19.
This is a pooled incidence in hospitalized patients, not a treatment effect. Timing, patient characteristics and any mortality result are not available in this summary.Adults with unresolved Long COVID had 38% lower adjusted relative odds of being in paid work at follow-up than adults with no or short-duration symptoms.
In a population-based England cohort of 45,864 participants employed at recruitment, 4% had unresolved Long COVID. This observational association does not establish causation.The review reported mortality estimates 6% to 13% higher per 4-week delay than with treatment without that additional delay; the cancer and treatment settings behind the range are not identified here.
This systematic review and meta-analysis assessed cancer treatment delay. The cancer types and treatments contributing to the reported range are not available in this summary.A systematic review and meta-analysis reported ocular manifestations in 11-36% of patients with COVID-19, ranging from conjunctivitis to retinal vascular changes.
This broad outcome combines different eye conditions; their timing, severity, and individual frequencies are not available in this summary.Among confirmed COVID-19 patients in Saudi Arabia, pooled anosmia prevalence was 44%; pooled taste dysfunction prevalence was 46%.
The review included predominantly self-reported measures. Methodological heterogeneity and the lack of a prospectively registered protocol limit interpretation.Within this study, 30-40% of the long COVID group met fibromyalgia criteria.
The proportion comes from this study's long COVID group; the study design and exact fibromyalgia criteria are not available in this summary.A systematic review reported microvascular thrombosis in 57-91% of COVID-19 autopsies, with multiple organ systems affected.
The range applies to reviewed COVID-19 autopsy findings; it does not estimate prevalence among all people with COVID-19.In a randomized, double-blind trial of adults hospitalized with COVID-19, baricitinib had a 43% lower relative hazard of mortality than placebo.
The statistic is a relative hazard, not an absolute percentage-point change in mortality.At 3 years after infection, adults with Long COVID had an 86% higher relative risk of depressive symptoms and a 60% higher relative risk of anxiety symptoms than adults without Long COVID.
This population-based prospective study reports associations at three-year follow-up; it cannot by itself establish causation.Ground-glass opacities appeared on chest CT in 83% of symptomatic COVID-19 patients.
The source is a systematic review and meta-analysis of imaging manifestations at admission. This result concerns CT, not chest ultrasound or radiographs.Compared with usual care, rehabilitation increased short-term 6-minute walking distance, with a mean difference of 102.34 m, and reduced modified Medical Research Council breathlessness scores and Hospital Anxiety and Depression Scale anxiety scores.
A systematic review and meta-analysis studied people with long COVID. The outcomes were short-term; the exact follow-up duration is not available in this summary.In the Swedish register-based cohort, women infected during pregnancy who had prior vaccination had lower preterm-birth hazard than infected women without previous vaccination. Both groups had higher hazard than non-infected women.
This was an observational comparison, so it does not establish a causal vaccine effect. The reported measures were relative hazards against non-infected women, not absolute risk differences.In a living systematic review of observational Omicron vaccine-effectiveness studies, 78% (1,591 results) were judged at serious risk of bias; confounding was the principal concern.
The appraisal covered 79 studies, over 53 million individuals and 2,032 vaccine-effectiveness estimates; 18% (361 results) were at moderate risk. These percentages concern study credibility, not the amount of vaccine effectiveness.A retrospective cohort study reported increased risk of autoimmune diseases affecting multiple organ systems after COVID-19.
The study concerned patients with COVID-19. The named reference group, follow-up and exact risk measure behind the reported percentage are not available in this summary.A meta-analysis reported 38.9% prevalence of clinically significant insomnia during acute COVID-19. A separate meta-analysis reported insomnia in 31% of those with Long COVID.
These were separate reviews, not a direct comparison between the acute COVID-19 and Long COVID groups. The acute estimate was described as higher than pre-pandemic rates.A study of SARS-CoV-2 cardiac involvement among young competitive athletes reported prolonged recovery lasting >90 days.
The recovery definition and the percentage's denominator are not available in this summary. The reported duration does not establish how often prolonged recovery occurred.For established Long COVID, neither the 15-day nor 25-day regimen established a benefit versus placebo on primary patient-reported autonomic, cognitive, or exercise outcomes.
The USA trial was randomized, double-blind, and placebo-controlled. Across all 963 participants, 42 (4%) experienced 52 serious adverse events, and there were no deaths; events were not reported as a between-group comparison.Among US Medicare beneficiaries aged 65 or older, death from any cause or hospitalization for specified heart and circulation problems within 1 year occurred in 48.8% after Omicron-era COVID-19 hospitalization versus 33.4% after historical 2017-2018 influenza hospitalization.
The combined outcome included death from any cause or hospitalization for heart attack, ischemic stroke, transient ischemic attack, blood clots in the lungs or deep veins, heart failure or cardiac arrest. The influenza group was historical; other design details are not recorded in this summary.View the full specialty index →
A headline finding from each specialty. Populations and comparisons differ; open a takeaway for the full context.